Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT04713982
PHASE2/PHASE3
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Sponsor: Vanderbilt University Medical Center
View on ClinicalTrials.gov
Summary
Examine the effects of deutetrabenazine on functional speech and gait impairment
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2021-11-19
Completion Date
2026-10-01
Last Updated
2026-01-21
Healthy Volunteers
No
Conditions
Interventions
DRUG
Deutetrabenazine
Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor
Locations (1)
Vanderbilt University Medical Center
Nashville, Tennessee, United States